Home > Cardiology > ACC 2022 > Myocardial Infarction > ICM-guided management did not improve MACE after MI

ICM-guided management did not improve MACE after MI

Presented By
Prof. Christian Jøns, Rigshospitalet, Denmark
Conference
ACC 2022
Trial
BIO|GUARD-MI
The BIO|GUARD-MI trial failed to meet its primary endpoint when no significant difference in major adverse cardiac events (MACE) emerged over 2.5 years in patients with myocardial infarction (MI) randomised to insertable cardiac monitor (ICM)-guided management or to standard care. Subanalyses did find a significant benefit for those at high risk. Presented by Prof. Christian Jøns (Rigshospitalet, Denmark), the findings and exploratory analyses of BIO|GUARD-MI (NCT02341534) which enrolled 802 patients, of whom 790 were randomised—average age of 72 years and 27% % women—randomised to either receive an ICM or standard of care [1]. Additional therapy for arrhythmias (i.e. oral anticoagulants, pacemakers, or β-blockers), including atrial fibrillation in 46.0% and bradycardia in 39.0%, was added to management in 39.0% of the ICM group and in 6.7% of the gro...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on